Relative risks and 95% CI for prostate cancer according to MnSOD genotype and quartiles of individual plasma antioxidant levels
| . | Quartile of prediagnostic plasma antioxidant level* . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | 1 . | 2 . | 3 . | 4 . | Pinteraction . | |||||
| All prostate cancer | ||||||||||
| Selenium (511 cases and 423 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.57 | 0.60 | 0.67 | 0.05 | |||||
| MnSOD AA | 1.49 | 0.80 | 0.59 | 0.47 (0.26-0.85)† | ||||||
| Lycopene (541 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.90 | 0.92 | 0.80 | 0.35 | |||||
| MnSOD AA | 1.49 | 0.78 | 1.08 | 0.84 (0.51-1.38)† | ||||||
| α-Tocopherol (541 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 1.16 | 1.17 | 1.14 | 0.13 | |||||
| MnSOD AA | 1.78 (1.01-3.12)† | 1.01 | 1.21 | 1.12 (0.67-1.88)† | ||||||
| Aggressive prostate cancer‡ | ||||||||||
| Selenium (251 cases and 423 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.71 | 0.64 | 0.74 | 0.01 | |||||
| MnSOD AA | 1.89 (1.01-3.56)† | 1.17 | 0.59 | 0.35 (0.15-0.82)† | ||||||
| Lycopene (261 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.78 | 0.94 | 0.70 | 0.23 | |||||
| MnSOD AA | 1.73 | 0.69 | 0.72 | 0.79 (0.43-1.48)† | ||||||
| α-Tocopherol (261 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 1.31 | 1.01 | 0.89 | 0.03 | |||||
| MnSOD AA | 1.97 (1.02-3.79)† | 1.20 | 1.01 | 0.72 (0.35-1.48)† | ||||||
| . | Quartile of prediagnostic plasma antioxidant level* . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | 1 . | 2 . | 3 . | 4 . | Pinteraction . | |||||
| All prostate cancer | ||||||||||
| Selenium (511 cases and 423 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.57 | 0.60 | 0.67 | 0.05 | |||||
| MnSOD AA | 1.49 | 0.80 | 0.59 | 0.47 (0.26-0.85)† | ||||||
| Lycopene (541 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.90 | 0.92 | 0.80 | 0.35 | |||||
| MnSOD AA | 1.49 | 0.78 | 1.08 | 0.84 (0.51-1.38)† | ||||||
| α-Tocopherol (541 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 1.16 | 1.17 | 1.14 | 0.13 | |||||
| MnSOD AA | 1.78 (1.01-3.12)† | 1.01 | 1.21 | 1.12 (0.67-1.88)† | ||||||
| Aggressive prostate cancer‡ | ||||||||||
| Selenium (251 cases and 423 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.71 | 0.64 | 0.74 | 0.01 | |||||
| MnSOD AA | 1.89 (1.01-3.56)† | 1.17 | 0.59 | 0.35 (0.15-0.82)† | ||||||
| Lycopene (261 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 0.78 | 0.94 | 0.70 | 0.23 | |||||
| MnSOD AA | 1.73 | 0.69 | 0.72 | 0.79 (0.43-1.48)† | ||||||
| α-Tocopherol (261 cases and 642 controls) | ||||||||||
| MnSOD VV and VA | 1.00 (Reference) | 1.31 | 1.01 | 0.89 | 0.03 | |||||
| MnSOD AA | 1.97 (1.02-3.79)† | 1.20 | 1.01 | 0.72 (0.35-1.48)† | ||||||
NOTE: RR and 95% CI were calculated using unconditional logistic regression, adjusted for age at baseline, smoking status, and duration of follow-up.
Based on each antioxidant, men were categorized into quartiles based on the quartile cutoff points among control subjects (batch-specific quartile cutoff points for all antioxidants except selenium).
RR (95% CI).
Aggressive prostate cancer, stage C or D, high-grade tumor (Gleason score 7-10), or prostate cancer deaths during the follow-up.